Cradle Secures $73M in Series B Funding to Advance AI-Powered Protein Engineering Platform
Cradle’s platform is used by industry leaders like Novo Nordisk, Johnson & Johnson Innovative Medicine, Novonesis, and Grifols.
Company Name: Cradle
Location: Amsterdam, the Netherlands
Industry: Biotechnology / AI Protein Engineering
Funding Details:
The $73M Series B round was led by IVP, with participation from existing investors Index Ventures and Kindred Capital.
Purpose of Investment:
The funding will accelerate the company’s platform development efforts to further enhance its applications in both pharmaceutical and industrial sectors.
Leadership:
- Stef van Grieken (CEO)
- Sam Partovi (Chief Commercial Officer): Recently appointed to expand Cradle’s biotech impact.
Product:
Cradle provides an AI-powered machine-learning platform designed to:
- Accelerate the development of therapeutics and bio-based products, including enzymes, antibodies, peptides, and vaccines.
- Adapt across pharmaceutical and industrial use cases, such as diagnostics, food, chemicals, and agricultural products.
The platform offers generative AI tools that enhance research and development capabilities, speeding up the innovation cycle in biotech.
About the Company:
Cradle’s platform is used by industry leaders like Novo Nordisk, Johnson & Johnson Innovative Medicine, Novonesis, and Grifols. With 40 team members, Cradle is recognized for its transformative role in biotechnology, providing tools that cater to a wide array of applications in therapeutics and industrial innovation.
